Silverback Therapeutics, Inc. (NASDAQ:SBTX) Holdings Decreased by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC decreased its holdings in shares of Silverback Therapeutics, Inc. (NASDAQ:SBTXGet Rating) by 7.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 82,033 shares of the company’s stock after selling 6,425 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Silverback Therapeutics were worth $433,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. acquired a new stake in Silverback Therapeutics during the second quarter valued at $35,000. AQR Capital Management LLC lifted its position in shares of Silverback Therapeutics by 81.2% in the second quarter. AQR Capital Management LLC now owns 19,845 shares of the company’s stock worth $84,000 after buying an additional 8,896 shares during the last quarter. Prelude Capital Management LLC increased its stake in shares of Silverback Therapeutics by 103.6% in the first quarter. Prelude Capital Management LLC now owns 34,000 shares of the company’s stock worth $119,000 after purchasing an additional 17,300 shares during the period. Bank of Montreal Can bought a new position in shares of Silverback Therapeutics in the second quarter worth about $206,000. Finally, Privium Fund Management UK Ltd bought a new position in shares of Silverback Therapeutics in the second quarter worth about $279,000. Institutional investors and hedge funds own 74.89% of the company’s stock.

Silverback Therapeutics Stock Performance

Silverback Therapeutics stock opened at $6.35 on Tuesday. The business’s 50-day simple moving average is $7.26 and its 200-day simple moving average is $5.93. The firm has a market capitalization of $228.97 million, a PE ratio of -2.62 and a beta of 0.60. Silverback Therapeutics, Inc. has a 52 week low of $2.80 and a 52 week high of $8.97.

About Silverback Therapeutics

(Get Rating)

Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.

Read More

Want to see what other hedge funds are holding SBTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Silverback Therapeutics, Inc. (NASDAQ:SBTXGet Rating).

Institutional Ownership by Quarter for Silverback Therapeutics (NASDAQ:SBTX)

Receive News & Ratings for Silverback Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silverback Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.